[1]
Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J. Systemic sclerosis. Nature reviews. Disease primers. 2015 Apr 23:1():15002. doi: 10.1038/nrdp.2015.2. Epub 2015 Apr 23
[PubMed PMID: 27189141]
[2]
Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis and rheumatism. 1988 Feb:31(2):196-203
[PubMed PMID: 3348823]
[3]
Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA Jr. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis and rheumatism. 2007 Aug:56(8):2740-6
[PubMed PMID: 17665460]
[4]
Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis and rheumatism. 1996 Aug:39(8):1362-70
[PubMed PMID: 8702445]
[5]
Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis and rheumatism. 2003 Jul:48(7):1956-63
[PubMed PMID: 12847690]
[6]
Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, Tan FK, McNearney T, Fischbach M, Fritzler MJ, Mayes MD, Reveille JD. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Annals of the rheumatic diseases. 2010 May:69(5):822-7. doi: 10.1136/ard.2009.111906. Epub 2009 Jul 12
[PubMed PMID: 19596691]
Level 3 (low-level) evidence
[7]
Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, Arnett FC, Mayes MD. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis and rheumatism. 2006 Dec:54(12):3945-53
[PubMed PMID: 17133608]
[8]
Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel PL, van 't Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF, Spanish Scleroderma Group, Airo P, van Laar J, Herrick A, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, de Baere E, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie BA, Hoffmann-Vold AM, Carreira P, Varga J, Hinchcliff M, Gregersen PK, Lee AT, Ying J, Han Y, Weng SF, Amos CI, Wigley FM, Hummers L, Nelson JL, Agarwal SK, Assassi S, Gourh P, Tan FK, Koeleman BP, Arnett FC, Martin J, Mayes MD. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature genetics. 2010 May:42(5):426-9. doi: 10.1038/ng.565. Epub 2010 Apr 11
[PubMed PMID: 20383147]
[9]
Allanore Y, Saad M, Dieudé P, Avouac J, Distler JH, Amouyel P, Matucci-Cerinic M, Riemekasten G, Airo P, Melchers I, Hachulla E, Cusi D, Wichmann HE, Wipff J, Lambert JC, Hunzelmann N, Tiev K, Caramaschi P, Diot E, Kowal-Bielecka O, Valentini G, Mouthon L, Czirják L, Damjanov N, Salvi E, Conti C, Müller M, Müller-Ladner U, Riccieri V, Ruiz B, Cracowski JL, Letenneur L, Dupuy AM, Meyer O, Kahan A, Munnich A, Boileau C, Martinez M. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS genetics. 2011 Jul:7(7):e1002091. doi: 10.1371/journal.pgen.1002091. Epub 2011 Jul 7
[PubMed PMID: 21750679]
[10]
Bossini-Castillo L, Martin JE, Broen J, Simeon CP, Beretta L, Gorlova OY, Vonk MC, Ortego-Centeno N, Espinosa G, Carreira P, García de la Peña P, Oreiro N, Román-Ivorra JA, Castillo MJ, González-Gay MA, Sáez-Comet L, Castellví I, Schuerwegh AJ, Voskuyl AE, Hoffmann-Vold AM, Hesselstrand R, Nordin A, Lunardi C, Scorza R, van Laar JM, Shiels PG, Herrick A, Worthington J, Fonseca C, Denton C, Tan FK, Arnett FC, Assassi S, Koeleman BP, Mayes MD, Radstake TR, Martin J, Spanish Scleroderma Group. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Annals of the rheumatic diseases. 2013 Apr:72(4):602-7. doi: 10.1136/annrheumdis-2012-201888. Epub 2012 Aug 15
[PubMed PMID: 22896740]
[11]
Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, Castellvi I, Vicente-Rabaneda E, Fonollosa V, Ortego-Centeno N, González-Gay MA, Espinosa G, Carreira P, Spanish Scleroderma Group, SLEGEN consortium, U.S. Scleroderma GWAS group, BIOLUPUS, Camps M, Sabio JM, D'alfonso S, Vonk MC, Voskuyl AE, Schuerwegh AJ, Kreuter A, Witte T, Riemekasten G, Hunzelmann N, Airo P, Beretta L, Scorza R, Lunardi C, Van Laar J, Chee MM, Worthington J, Herrick A, Denton C, Fonseca C, Tan FK, Arnett F, Zhou X, Reveille JD, Gorlova O, Koeleman BP, Radstake TR, Vyse T, Mayes MD, Alarcón-Riquelme ME, Martin J. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human molecular genetics. 2013 Oct 1:22(19):4021-9. doi: 10.1093/hmg/ddt248. Epub 2013 Jun 4
[PubMed PMID: 23740937]
[12]
Assassi S, Radstake TR, Mayes MD, Martin J. Genetics of scleroderma: implications for personalized medicine? BMC medicine. 2013 Jan 11:11():9. doi: 10.1186/1741-7015-11-9. Epub 2013 Jan 11
[PubMed PMID: 23311619]
[13]
Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P, Lin NY, Beyer C, Distler O, Schett G, Distler JH. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Annals of the rheumatic diseases. 2014 Jun:73(6):1232-9. doi: 10.1136/annrheumdis-2012-203194. Epub 2013 May 22
[PubMed PMID: 23698475]
[14]
Altorok N, Tsou PS, Coit P, Khanna D, Sawalha AH. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Annals of the rheumatic diseases. 2015 Aug:74(8):1612-20. doi: 10.1136/annrheumdis-2014-205303. Epub 2014 May 8
[PubMed PMID: 24812288]
[15]
Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, Wei J, Varga J. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis. The Journal of investigative dermatology. 2013 May:133(5):1302-10. doi: 10.1038/jid.2012.479. Epub 2013 Jan 10
[PubMed PMID: 23303459]
[16]
Noda S, Asano Y, Nishimura S, Taniguchi T, Fujiu K, Manabe I, Nakamura K, Yamashita T, Saigusa R, Akamata K, Takahashi T, Ichimura Y, Toyama T, Tsuruta D, Trojanowska M, Nagai R, Sato S. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nature communications. 2014 Dec 12:5():5797. doi: 10.1038/ncomms6797. Epub 2014 Dec 12
[PubMed PMID: 25504335]
[17]
Wang YY, Wang Q, Sun XH, Liu RZ, Shu Y, Kanekura T, Huang JH, Li YP, Wang JC, Zhao M, Lu QJ, Xiao R. DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. The British journal of dermatology. 2014 Jul:171(1):39-47. doi: 10.1111/bjd.12913. Epub 2014 Jul 6
[PubMed PMID: 24641670]
[18]
Muryoi T, Kasturi KN, Kafina MJ, Cram DS, Harrison LC, Sasaki T, Bona CA. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. The Journal of experimental medicine. 1992 Apr 1:175(4):1103-9
[PubMed PMID: 1372644]
[19]
Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature medicine. 2000 Oct:6(10):1183-6
[PubMed PMID: 11017152]
[20]
Markiewicz M, Smith EA, Rubinchik S, Dong JY, Trojanowska M, LeRoy EC. The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clinical and experimental rheumatology. 2004 Jan-Feb:22(3 Suppl 33):S31-4
[PubMed PMID: 15344595]
[21]
McCormic ZD, Khuder SS, Aryal BK, Ames AL, Khuder SA. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. International archives of occupational and environmental health. 2010 Oct:83(7):763-9. doi: 10.1007/s00420-009-0505-7. Epub 2010 Jan 3
[PubMed PMID: 20047060]
Level 1 (high-level) evidence
[22]
Nietert PJ, Sutherland SE, Silver RM, Pandey JP, Knapp RG, Hoel DG, Dosemeci M. Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis and rheumatism. 1998 Jun:41(6):1111-8
[PubMed PMID: 9627022]
[23]
Tabuenca JM. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet (London, England). 1981 Sep 12:2(8246):567-8
[PubMed PMID: 6116011]
[24]
Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. The New England journal of medicine. 1990 Mar 29:322(13):869-73
[PubMed PMID: 2314421]
[25]
Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A. Bleomycin-induced scleroderma. The Journal of rheumatology. 1980 Sep-Oct:7(5):651-9
[PubMed PMID: 6160247]
[26]
Wu M, Varga J. In perspective: murine models of scleroderma. Current rheumatology reports. 2008 Jul:10(3):173-82
[PubMed PMID: 18638424]
Level 3 (low-level) evidence
[27]
De Angelis R, Bugatti L, Cerioni A, Del Medico P, Filosa G. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clinical rheumatology. 2003 Feb:22(1):49-52
[PubMed PMID: 12605319]
[28]
Johnson KL, Nelson JL, Furst DE, McSweeney PA, Roberts DJ, Zhen DK, Bianchi DW. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis and rheumatism. 2001 Aug:44(8):1848-54
[PubMed PMID: 11508438]
[29]
Artlett CM, Welsh KI, Black CM, Jimenez SA. Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis. Immunogenetics. 1997:47(1):17-22
[PubMed PMID: 9382916]
[30]
Lambert NC, Evans PC, Hashizumi TL, Maloney S, Gooley T, Furst DE, Nelson JL. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. Journal of immunology (Baltimore, Md. : 1950). 2000 Jun 1:164(11):5545-8
[PubMed PMID: 10820227]
[31]
Peoples C, Medsger TA Jr, Lucas M, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. Journal of scleroderma and related disorders. 2016 May-Aug:1(2):177-240. doi: 10.5301/jsrd.5000209. Epub 2016 Jul 23
[PubMed PMID: 29242839]
[32]
Steen VD. Autoantibodies in systemic sclerosis. Seminars in arthritis and rheumatism. 2005 Aug:35(1):35-42
[PubMed PMID: 16084222]
[33]
Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nature reviews. Rheumatology. 2010 Feb:6(2):112-6. doi: 10.1038/nrrheum.2009.238. Epub
[PubMed PMID: 20125179]
[34]
Ranque B, Authier FJ, Berezne A, Guillevin L, Mouthon L. Systemic sclerosis-associated myopathy. Annals of the New York Academy of Sciences. 2007 Jun:1108():268-82
[PubMed PMID: 17899625]
[35]
Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford, England). 2006 Oct:45 Suppl 4():iv14-7
[PubMed PMID: 16980717]
[36]
Parks JL, Taylor MH, Parks LP, Silver RM. Systemic sclerosis and the heart. Rheumatic diseases clinics of North America. 2014 Feb:40(1):87-102. doi: 10.1016/j.rdc.2013.10.007. Epub 2013 Nov 7
[PubMed PMID: 24268011]
[37]
Desai CS, Lee DC, Shah SJ. Systemic sclerosis and the heart: current diagnosis and management. Current opinion in rheumatology. 2011 Nov:23(6):545-54. doi: 10.1097/BOR.0b013e32834b8975. Epub
[PubMed PMID: 21897256]
Level 3 (low-level) evidence
[38]
Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kötter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the rheumatic diseases. 2010 Oct:69(10):1809-15. doi: 10.1136/ard.2009.114264. Epub 2010 Jun 15
[PubMed PMID: 20551155]
[39]
Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clinical and experimental rheumatology. 2010 Sep-Oct:28(5 Suppl 62):S48-53
[PubMed PMID: 21050545]
[40]
Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clinical and experimental rheumatology. 2012 Mar-Apr:30(2 Suppl 71):S30-7
[PubMed PMID: 22338601]
[41]
Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. American heart journal. 1993 Jan:125(1):194-203
[PubMed PMID: 8417518]
[42]
Ayers NB, Sun CM, Chen SY. Transforming growth factor-β signaling in systemic sclerosis. Journal of biomedical research. 2018 Jan 18:32(1):3-12. doi: 10.7555/JBR.31.20170034. Epub
[PubMed PMID: 29353817]
[43]
Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M, De Luca G, Laria A, Meduri A, Bellocci F, Bonomo L, Crea F, Ferraccioli G. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Seminars in arthritis and rheumatism. 2014 Feb:43(4):526-35. doi: 10.1016/j.semarthrit.2013.07.006. Epub 2013 Aug 6
[PubMed PMID: 23932313]
[44]
West SG, Killian PJ, Lawless OJ. Association of myositis and myocarditis in progressive systemic sclerosis. Arthritis and rheumatism. 1981 May:24(5):662-8
[PubMed PMID: 7236323]
[45]
D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. The American journal of medicine. 1969 Mar:46(3):428-40
[PubMed PMID: 5780367]
Level 3 (low-level) evidence
[46]
Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation. 1976 Mar:53(3):483-90
[PubMed PMID: 1248080]
[47]
Faccini A, Agricola E, Oppizzi M, Margonato A, Galderisi M, Sabbadini MG, Franchini S, Camici PG. Coronary microvascular dysfunction in asymptomatic patients affected by systemic sclerosis - limited vs. diffuse form. Circulation journal : official journal of the Japanese Circulation Society. 2015:79(4):825-9. doi: 10.1253/circj.CJ-14-1114. Epub 2015 Feb 6
[PubMed PMID: 25740209]
[48]
Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner HN Jr, Brinker JA, Ciuffo AA, Becker LC. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Annals of internal medicine. 1986 Nov:105(5):661-8
[PubMed PMID: 3767147]
[49]
Mavrogeni SI, Bratis K, Karabela G, Spiliotis G, Wijk Kv, Hautemann D, Reiber JH, Koutsogeorgopoulou L, Markousis-Mavrogenis G, Kolovou G, Stavropoulos E. Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. Inflammation & allergy drug targets. 2015:14(1):29-36
[PubMed PMID: 26374223]
[50]
Paik JJ, Wigley FM, Mejia AF, Hummers LK. Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma. Arthritis care & research. 2016 Nov:68(11):1695-1703. doi: 10.1002/acr.22870. Epub 2016 Oct 9
[PubMed PMID: 26881982]
[51]
Miller WL. Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed. Circulation. Heart failure. 2016 Aug:9(8):e002922. doi: 10.1161/CIRCHEARTFAILURE.115.002922. Epub
[PubMed PMID: 27436837]
[52]
Bissell LA, Anderson M, Burgess M, Chakravarty K, Coghlan G, Dumitru RB, Graham L, Ong V, Pauling JD, Plein S, Schlosshan D, Woolfson P, Buch MH. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford, England). 2017 Jun 1:56(6):912-921. doi: 10.1093/rheumatology/kew488. Epub
[PubMed PMID: 28160468]
Level 3 (low-level) evidence
[53]
Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M, EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the rheumatic diseases. 2011 Mar:70(3):476-81. doi: 10.1136/ard.2010.136929. Epub 2010 Nov 15
[PubMed PMID: 21081523]
Level 3 (low-level) evidence
[54]
Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, Matucci-Cerinic M, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirják L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli A, Krummel-Lorenz B, Rednic S, Allanore Y, Müeller-Ladner U. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Annals of the rheumatic diseases. 2019 Nov:78(11):1576-1582. doi: 10.1136/annrheumdis-2019-215486. Epub 2019 Aug 7
[PubMed PMID: 31391176]
[55]
Winter MP, Sulzgruber P, Koller L, Bartko P, Goliasch G, Niessner A. Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis. Heart failure reviews. 2018 Jul:23(4):573-581. doi: 10.1007/s10741-018-9709-9. Epub
[PubMed PMID: 29862463]
Level 1 (high-level) evidence
[56]
Stack J, McLaughlin P, Sinnot C, Henry M, MacEneaney P, Eltahir A, Harney S. Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone. Scandinavian journal of rheumatology. 2010 Aug:39(4):349-50. doi: 10.3109/03009740903493741. Epub
[PubMed PMID: 20476869]
[57]
Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Seminars in arthritis and rheumatism. 2006 Jun:35(6):355-9
[PubMed PMID: 16765712]
Level 3 (low-level) evidence
[58]
Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. Journal of the American Academy of Dermatology. 2001 Feb:44(2):273-81
[PubMed PMID: 11174386]
[59]
Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Transactions of the Association of American Physicians. 1975:88():70-86
[PubMed PMID: 1224441]
[60]
Sehgal VN, Srivastava G, Aggarwal AK, Behl PN, Choudhary M, Bajaj P. Localized scleroderma/morphea. International journal of dermatology. 2002 Aug:41(8):467-75
[PubMed PMID: 12207760]
[61]
Candell-Riera J, Armadans-Gil L, Simeón CP, Castell-Conesa J, Fonollosa-Pla V, García-del-Castillo H, Vaqué-Rafart J, Vilardell M, Soler-Soler J. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis and rheumatism. 1996 Jul:39(7):1138-45
[PubMed PMID: 8670322]
[62]
Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, Te Boome L, van Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. The American journal of medicine. 2005 Jan:118(1):2-10
[PubMed PMID: 15639201]
Level 1 (high-level) evidence
[63]
Al-Dhaher FF,Pope JE,Ouimet JM, Determinants of morbidity and mortality of systemic sclerosis in Canada. Seminars in arthritis and rheumatism. 2010 Feb
[PubMed PMID: 18706680]
[64]
Czirják L, Kumánovics G, Varjú C, Nagy Z, Pákozdi A, Szekanecz Z, Szucs G. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Annals of the rheumatic diseases. 2008 Jan:67(1):59-63
[PubMed PMID: 17519276]